High‐resolution accurate mass approach to characterization of SCO‐267 metabolites using liquid chromatography hybrid quadrupole Orbitrap mass spectrometry

Abstract

RationaleSCO‐267 is a potent full agonist of G‐protein‐coupled receptor 40. As a promising therapeutic agent for type 2 diabetes mellitus, it is necessary to elucidate its metabolite profiles during the stage of drug development for safety considerations.MethodsThe in vitro metabolism was investigated by incubating SCO‐267 (5 μM) with liver microsomes and hepatocytes (rat and human). For in vivo metabolism, SCO‐267 (10 mg/kg) was orally administered to rats and plasma samples were collected. The metabolites were identified via measurements of accurate mass, elemental composition and product ions using liquid chromatography coupled to hybrid quadrupole Orbitrap high‐resolution mass spectrometry (LC‐Orbitrap‐MS).ResultsA total of 19 metabolites were structurally identified. M2 (hydroxyl‐SCO‐267), M15 (SCO‐267‐acyl‐glucuronide), M16 (desmethyl‐SCO‐267) and M17 (desneopentyl‐SCO‐267) were verified with reference standards. M2, M11, M16 and M17 were the major metabolites originating from hydroxylation, O‐demethylation and N‐dealkylation, respectively. Phenotyping study with recombinant human P450 enzymes demonstrated that hydroxylation (M2 and M11) was mainly catalyzed by CYP2C8 and 3A4; demethylation (M16) was mainly catalyzed by CYP2D6, and less catalyzed by CYP2C8 and 3A4; and N‐dealkylation (M17) was exclusively triggered by CYP3A4.ConclusionsHydroxylation, O‐demethylation, N‐dealkylation and acyl glucuronidation were the major metabolic pathways of SCO‐267. This study is the first to discover the metabolic fates of SCO‐267, which provides a basis for safety assessment of this drug candidate.